Life Science Investing Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Life Science Investing Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Life Science Investing Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting
Life Science Investing Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
